Famciclovir is the well-absorbed (77% bioavailable) (9) oral form of penciclovir, a novel, selective antiviral agent with activity against varicella-zoster virus (VZV), herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and Epstein-Barr virus (2, 16) . Both the relative and absolute potencies of penciclovir and acyclovir are dependent on the host cell and assay method used, and inhibitory concentrations are generally comparable in vitro (1) (2) (3) . However, the active triphosphate form of penciclovir has a prolonged intracellular half-life in both HSV (10 to 20 h)-and VZV-infected cells (9.1 h) compared with that of acyclovir triphosphate (<1 h for both HSV-and VZV-infected cells) (4, 12, 15) .
The most common adverse reactions reported in clinical studies with acyclovir include nausea and/or vomiting, diarrhea, headache, and rash (7) . In addition, malaise was reported in patients who received acyclovir for herpes zoster (8) . The safety and efficacy of famciclovir have been assessed in clinical trials of patients with herpes zoster and genital herpes (10, 11, 13) . Safety reporting from individual ongoing and completed clinical studies demonstrate that famciclovir has been tolerated well by over Adverse experiences. The incidence and severity of adverse experiences reported as related to study medication administration (includes the categories of related, probably related, possibly related, and causalities which were unassessable or not indicated) were comparable between the famciclovir and placebo groups. Headache, nausea, and diarrhea were the most common adverse experiences reported. Headaches were reported in 9.3% of patients receiving famciclovir and 7.9% of patients receiving placebo. Nausea and diarrhea were less common, with 4.5 and 4.2% of patients reporting nausea and 2.4 and 2.3% reporting diarrhea in the famciclovir and placebo groups, respectively. All other adverse experiences occurred in <2% of the patient population. events occurred only once. The overall withdrawal rates due to adverse experiences were similar in the famciclovir (2.4%) and placebo (1.6%) groups. The leading cause of withdrawal for famciclovir recipients was nausea (0.7%), whereas placebo recipients withdrew because of worsening of herpes zoster (0.5%). Adverse experiences leading to withdrawal that were considered to be related or probably related to study medication administration occurred in 0.5% of both the famciclovir and placebo patient populations. No deaths were attributed to treatment with famciclovir.
The adverse experience profile for famciclovir did not vary considerably when the data were analyzed by duration of therapy and by condition under study. For example, headache, nausea, diarrhea, and fatigue were the most frequently reported adverse experiences for short-term studies (i.e., all trials except the two genital herpes suppression studies) and herpes zoster studies. The incidence of each adverse experience was comparable between the famciclovir and placebo groups in both subsets.
The control group for two of the three randomized, doubleblind studies of patients with herpes zoster received acyclovir. Table 3 summarizes the numbers of famciclovir-and acyclovirtreated patients and incidences of adverse experiences for all events reported as related to study medication which occurred with a frequency of .1% in these two acyclovir-controlled studies. As with the overall famciclovir patient population, headache (6.0%) and nausea (3.7%) were the most frequently reported adverse experiences for famciclovir-treated patients. The most common adverse experiences reported for acyclovirtreated patients were headache (4.6%), nausea (2.7%), abdominal pain (2.3%), and fatigue (2.3%).
Laboratory assessments. There was no consistent association between treatment with famciclovir or duration of exposure to famciclovir and the incidence of laboratory abnormalities. Table 4 summarizes values of potential clinical concern for representative laboratory parameters. Less than 1% of the total patient population treated with famciclovir had values of potential clinical concern, with the exception of increases in alanine transaminase (1.4%) and serum phosphate (2.5%). In both cases, however, increases were also observed in alanine transaminase (1.2%) and serum phosphate (1.5%) for patients who received placebo.
Laboratory parameters related to hematology, hepatic function, renal function, serum electrolytes, muscle metabolism, bone metabolism, and glucose were examined for mean changes from baseline. No clinically significant differences between the famciclovir and placebo groups were observed. Similarly, famciclovir administration did not lead to any clinically relevant changes in urinalysis parameters.
Discussion. Biochemical studies on the mode of action of penciclovir (14) have shown that the preferential phosphorylation in herpesvirus-infected cells is even more marked for penciclovir than for acyclovir. The minimal phosphorylation of penciclovir in uninfected cells, together with the low activity of penciclovir triphosphate against cellular DNA polymerases, provides a rationale for the lack of toxicity of penciclovir in cell culture. This hypothesis has been tested in a wide range of human cell lines of differing tissue origin (2) . These tests showed that penciclovir is like acyclovir in being exceptionally nontoxic to replicating cells in culture. Furthermore, evaluations of famciclovir and penciclovir in toxicological tests have shown that these compounds have a good safety profile, similar to that of acyclovir.
The ability of penciclovir triphosphate to inhibit DNA chain elongation was investigated in vitro. Under conditions designed to represent physiological concentrations of nucleoside triphosphates found within virus-infected cells in combination with penciclovir triphosphate or acyclovir triphosphate, penciclovir triphosphate (non-obligate chain terminator) was more effective than acyclovir triphosphate (obligate chain terminator) in inhibiting viral (HSV-2) DNA polymerase-mediated DNA chain elongation (4, 5, 14) . Famciclovir and acyclovir, with safety profiles comparable to that of placebo, are nucleoside analogs, a drug class which has been associated with adverse effects on testicular function. The potential for testicular effects was investigated in a study which included 67 men (34 famciclovir recipients and 33 placebo recipients) with recurrent genital herpes. Patients were randomized to receive either famciclovir (250 mg) or placebo twice daily for 18 weeks. Semen samples were provided every other week in the 8-week pretreatment period, during treatment, and in the 8-week posttreatment period. No significant effects of treatment were found upon proportions of dead, motile, or normal sperm or any other semen parameter, and famciclovir was tolerated well by study participants (10) .
The favorable safety profile of famciclovir demonstrated by this integrated safety analysis is particularly noteworthy when viewed in relation to the current therapies available for the treatment of herpesvirus infections. Famciclovir is the only antiherpes agent other than acyclovir which exhibits a safety profile comparable to that of placebo both during short-term (5 to 7 days) and long-term (18 weeks) exposure. Ganciclovir, a nucleoside analog with a broad spectrum of activity against herpesviruses (HSV-1, HSV-2, VZV, cytomegalovirus, and Epstein-Barr virus), is considerably more toxic than either famciclovir or acyclovir and therefore is indicated primarily for the treatment of life-or sight-threatening cytomegaloviruscaused disease in immunocompromised patients (6) . Similarly, foscarnet, a non-nucleoside analog with an in vitro spectrum of activity similar to that of ganciclovir, is limited in indication to the treatment of cytomegalovirus-caused retinitis in immunocompromised patients because of the potential for renal impairment.
The biochemical properties and safety profile of famciclovir favor its use for the treatment of herpesvirus infections, an area where treatment alternatives with acceptable safety profiles are limited. This integrated safety evaluation of over 1,600 patients who received famciclovir in 13 completed clinical studies of patients with herpes zoster or genital herpes demonstrates that famciclovir is tolerated well and exhibits a safety profile comparable to that of placebo.
